Compare ONEW & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | VYGR |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 193.5M |
| IPO Year | 2019 | 2015 |
| Metric | ONEW | VYGR |
|---|---|---|
| Price | $9.65 | $2.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $13.33 | ★ $14.89 |
| AVG Volume (30 Days) | 88.0K | ★ 454.1K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.85 | $129.75 |
| P/E Ratio | $3.53 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $2.58 |
| 52 Week High | $17.35 | $5.55 |
| Indicator | ONEW | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 28.81 |
| Support Level | $9.04 | N/A |
| Resistance Level | $9.83 | $3.30 |
| Average True Range (ATR) | 0.61 | 0.12 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 20.53 | 12.70 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.